PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
Guardant Health to Integrate Lunit's AI PD-L1 Scoring Algorithm Into Tissue Test Offering
The companies have been working together since 2021 following a strategic investment by Guardant in the South Korean AI firm.
Roche Gains IVDR Certificate for Cancer Treatment Companion Dx
TÜV SÜD, a European notified body, claimed it to be the first such certification of its kind.
Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq
The test gained European approval to identify PD-L1-expressing non-small cell lung cancer patients eligible for treatment with Roche's checkpoint inhibitor.
Blood-Based PD-L1 Tracking Could Offer Improved Response Prediction for Lung Cancer Immunotherapy
Premium
While the results are from a small study, investigators are working to validate them in larger groups, hoping their method can prove itself for clinical use.
Lunit Gets CE Mark for AI-Based PD-L1 Expression Test
The South Korean biotech company plans to launch the Lunit Scope PD-L1 test in Europe in the second half of this year.
Oct 27, 2020
Inspirata, Flagship Bio Enter Digital Pathology Pact
Nov 22, 2019